NEW YORK, April 18, 2012 /PRNewswire/ -- Harwood
Feffer LLP (www.hfesq.com) is investigating potential claims
against the board of directors of Catalyst Health Solutions, Inc.
("Catalyst" or the "Company") (NASDAQ: CHSI) concerning the
proposed acquisition of the Company by SXC Health Solutions ("SXC")
in a transaction valued at approximately $4.4 billion.
(Logo:
http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )
On April 18, 2012, it was
announced that Catalyst and SXC have entered into a definitive
agreement pursuant to which SXC will acquire Catalyst. Under
the agreement, Catalyst shareholders will receive $28.00 in cash and 0.6606 shares of SXC stock per
Catalyst share held, for an approximate combined value of
$81.02 per Catalyst share.
Our investigation concerns whether the Catalyst board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company
shareholders.
If you own Catalyst shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Benjamin Sachs-Michaels
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers:
(877) 935-7400
(212) 935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2011 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP
(www.hfesq.com). Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP